Financial Report

Notes to the consolidated financial statements

1 General

General

PolyPeptide Group AG (the “Company”) is the holding company of a group of companies (the “Group”) engaged in the development, manufacturing and marketing of peptide- and oligonucleotide-based compounds for use in the pharmaceutical and related research industries. The Group offers a full service concept from early stage custom development to contract manufacturing in both solid phase and solution phase technology. In addition, the Group companies also market a wide range of generic peptides.

In 2007, PolyPeptide Laboratories Holding B.V. (incorporated under the laws of the Netherlands) became the holding company of the Group, which consisted of six integrated operating subsidiaries located in Sweden, USA, France, India and Belgium, plus a holding company located in Sweden, a dormant company located in Denmark, and a dormant company located in Germany, which has since been merged into the Swedish holding company in 2022.

As part of the preparations for the IPO on SIX Swiss Exchange on 29 April 2021, all the shares of PolyPeptide Laboratories Holding B.V. were contributed into the new Swiss entity, PolyPeptide Group AG, in the form of a capital contribution. As a result, PolyPeptide Group AG became the new parent holding company of the Group.

PolyPeptide Group AG (the “Company”) was incorporated in Switzerland on 6 April 2021. The registered office of the Company is Neuhofstrasse 24, 6340 Baar, Switzerland.
As at 31 December 2022, the Company was a 55.47% subsidiary of Draupnir Holding B.V., a company registered in the Netherlands. Draupnir Holding B.V.'s ultimate parent entity is Cryosphere Foundation, a foundation registered on Guernsey of which Mr. Frederik Paulsen (Lausanne, Switzerland) is at present the principal beneficiary pursuant to the charter of the foundation governed by the laws of Guernsey, although he has no vested interest in any portion of the foundation assets.

1 Summary of significant accounting policies

Basis of preparation

The consolidated financial statements of PolyPeptide Group AG and its subsidiaries have been prepared in accordance with the International Financial Reporting Standards (IFRS).

The financial year for the Group is 1 January – 31 December 2022.

All amounts are stated in thousands of Euros, unless otherwise indicated.

Changes in accounting policies and presentation

The following amendments became mandatorily effective from 1 January 2022:

  • Amendments to IFRS 3, IFRS 9, IFRS 16, IAS 16, IAS 37 and IAS 41

The adoption of these amendments to the IFRS Standards has not had any significant impact on the financial statements of the Group.

As a result, the accounting policies are consistent with prior years. 

Principles of consolidation

The consolidated financial statements include the Company and its subsidiaries as at 31 December of each year. Subsidiaries are all entities over which the Group has control. The Group controls an entity where the Group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are consolidated from the date the Company obtains control until such time as control ceases.

The financial statements of the subsidiaries are prepared for the same reporting year as the parent company, using consistent accounting policies. Reference is made to Note 11 for information regarding the consolidated subsidiaries. All intra-group balances, income and expenses and unrealized gains and losses resulting from intra-group transactions are eliminated in full. A change in the ownership interest of a subsidiary, without loss of control, is accounted for as an equity transaction.

Translation of foreign currencies

The Group’s consolidated financial statements are presented in Euros. The functional currency of the parent company is Swiss Franc (CHF). Each entity within the Group determines its own functional currency and items included in the financial statements of each entity are measured using that functional currency.

Translation of transactions and balances
Transactions in foreign currencies are initially recorded by the Group’s entities at their functional currency spot rate at the date the transaction first qualifies for recognition. Monetary assets and liabilities denominated in foreign currencies are retranslated at the functional currency spot rate of exchange at the reporting date. Differences arising on settlement or translation of monetary items are recognized in the income statement.

Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using exchange rates as at the dates of the initial transactions. When a gain or loss on a non‑monetary item is recognized in other comprehensive income, any exchange component of that gain or loss is recognized in other comprehensive income. Conversely, when a gain or loss on a non‑monetary item is recognized in profit or loss, any exchange component of that gain or loss is recognized in profit or loss.

Translation of subsidiaries
The functional currencies of the foreign operations are the Euro, US Dollar, Indian Rupee, and the Swedish Krona. As at the reporting date, the assets and liabilities of the subsidiaries with a functional currency other than the Euro are translated into the presentation currency of the Group (the Euro) at the rate of exchange ruling at the reporting date and their income statements are translated at the weighted average exchange rates for the year. The exchange differences arising on the translation are recorded in other comprehensive income. On disposal of a foreign entity, the component of other comprehensive income relating to that foreign operation is recognized in the income statement.

Any goodwill arising on the acquisition of a foreign operation and any fair value adjustments to the carrying amounts of assets and liabilities arising from the acquisition are treated as assets and liabilities of the foreign operation and translated at the closing rate.

Revenue recognition

Revenue is recognized to the extent it is probable that the economic benefits will flow to the Group and the revenue can be reliably measured, regardless of when the payment is being made. Revenue is measured at the fair value of the consideration received, excluding discounts, rebates, VAT and other taxes and duties. Revenue is recognized when a performance obligation is satisfied.

Performance obligations and timing of revenue recognition
The Group earns the majority of its revenues from the sale of goods. Therefore, most of the Group’s revenues are recognized at a point in time when control of the goods has transferred to the customer. This is generally when the goods are delivered to the customer. There is limited judgement needed in identifying the point in time when control passes: once physical delivery of the products to the agreed location has occurred, the Group no longer has physical possession, usually will have a present right to payment (as a single payment on delivery) and retains none of the significant risks and rewards of the goods in question. The Group has no sales contracts that include performance obligations relating to warranties or returns.

The Group also incurs a portion of its revenues in connection with pharmaceutical services like development and analytical services. In some cases, these contracts run longer than a year with revenue recognized typically on an over time basis. These service contracts are set up in a way to be distinct and the consideration related to the services is based upon standard hourly prices. For these services, the Group recognizes revenues based upon stage of completion which is estimated by comparing the number of hours actually spent on the project with the total number of hours expected to complete the project (i.e. an input-based method). This is considered a faithful depiction of the transfer of services as the contracts are initially priced on the basis of anticipated hours to complete the projects and therefore also represent the amount to which the Group would be entitled to based on its performance to date.

Determining the transaction price
With respect to the sale of goods, a transaction price is agreed in an order or order confirmation, between the Group and its customer. Prices may also be included in the master service agreements, which are usually updated every year. However, the price in the order confirmation is leading. There are no other variable components included in the transaction price such as financing components, payables to the customer, non-cash considerations, etc. All other special considerations such as volume discounts are calculated on a calendar-year basis and therefore do not result in any uncertainties about the amount of the transaction price at the end of the financial year. The transaction price for services is based upon a price list with standard prices (fair value) for different kind of services.

Allocating amounts to performance obligations
As each performance obligation in a customer contract is generally priced against its fair value, only limited judgment is involved in the allocation of the total contract price to the individual performance obligations. This allocation will usually be determined by dividing the total contract price by the number of units ordered or hours spent.

Other income and expenses

Interest
For all financial instruments measured at amortized cost, interest income or expense is recorded using the effective interest rate. Interest income and expense is included in financial income and expense in the income statement.

Other income, costs and expenses
Other income, costs and expenses are allocated to the year to which they relate. Losses are accounted for in the year in which they arise.

Research expenses

Research expenses relating to Custom Projects are included in ‘Cost of sales’ in the income statement. Research expenses not relating to Custom Projects are presented on the separate financial line item ‘Research expenses’ in the income statement.

Share-based payment

Share-based compensation is provided to members of the Board of Directors, the Executive Committee and certain other senior managers (as applicable).

The programs are classified as equity arrangements where the fair value of the shares granted under the programs are recognized as an expense with a corresponding increase in equity. The fair value of the shares is measured at the market share price of PolyPeptide Group AG’s shares, adjusted to take into account terms and conditions upon which the shares were granted.
The total expense is recognized over the vesting period, which is the period over which all of the specified vesting conditions are to be satisfied. At the end of each period, the Company revises its estimates of the number of shares that are expected to vest based on the non-market vesting and service conditions. It recognizes the impact of the revision to original estimates, if any, in the income statement, with a corresponding adjustment to equity.

Government grants

Government grants are recognized when there is reasonable assurance that the grant will be received and all associated conditions will be complied with. When the grant relates to an expense item, it is recognized as other operating income over the period necessary to match the grant on a systematic basis to the costs that it is intended to compensate. When the grant relates to an asset, it is recognized as deferred income and released to other operating income in equal annual amounts over the expected useful life of the related asset.

Tax credits that can only be realized by a reduction of current or future corporate tax payments, rather than being directly settled in cash, are presented as part of the income tax charge for the year.

Taxes

Current income tax
Current income tax assets and liabilities for the current and prior periods are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted by the reporting date. Corporate income tax is calculated on taxable profit according to the applicable tax rates in the various countries.

Current income tax relating to items recognized outside profit or loss is recognized outside profit or loss. Current income tax items are recognized in correlation to the underlying transaction either in profit or loss, through other comprehensive income or directly in equity.

Deferred income tax
Deferred income tax is provided using the liability method on temporary differences between the tax bases of assets and liabilities at the reporting date and their carrying amounts for financial reporting purposes.

Deferred income tax liabilities are recognized for all taxable temporary differences, except:

  • When the deferred income tax liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; and
  • in respect to taxable temporary differences associated with investments in subsidiaries, when the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future.

Deferred income tax assets are recognized for all deductible temporary differences, the carry-forward of unused tax credits and any unused tax losses.

Deferred tax assets are recognized to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry-forward of unused tax credits and unused tax losses can be utilized, except:

  • When the deferred income tax asset relating to the deductible temporary difference arises from initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither accounting profit nor taxable profit or loss; and
  • in respect of deductible temporary differences associated with investments in subsidiaries, associates and interests in joint ventures, deferred tax assets are only recognized to the extent that it is probable that the temporary differences will reverse in the foreseeable future and taxable profit will be available against which the temporary differences can be utilized.

The carrying amount of deferred income tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred income tax asset to be utilized. Unrecognized deferred income tax assets are reassessed at each reporting date and are recognized to the extent that it is probable that future taxable profit will allow the deferred tax asset to be recovered.

Deferred income tax assets and liabilities are measured at the tax rates that are expected to apply to the year when the assets are realized and the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date.

Deferred income tax relating to items recognized outside profit or loss is recognized outside profit or loss. Deferred tax items are recognized in correlation to the underlying transaction in other comprehensive income or directly in to equity.

Deferred income tax assets and deferred income tax liabilities are offset, if a legally enforceable right exists to set off current tax assets against current income tax liabilities and the deferred income taxes relate to the same taxable entity and the same taxation authority.

VAT
Income, expenses and assets are recognized net of the amount of VAT, except:

  • When the VAT incurred on a purchase of goods and services is not recoverable from the taxation authority, in which case the VAT is recognized as part of the cost of acquisition of the asset or as part of the expense item as applicable; and
  • receivables and payables are stated with the amount of VAT included.

The net amount of VAT recoverable from, or payable to, the taxation authority is included as part of receivables or payables in the statement of financial position.

Fair value measurements

The Group measures certain financial instruments at fair value. The fair values of financial instruments measured at amortized costs are disclosed in the financial statements. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

  • In the principal market for the asset or liability; or
  • in the absence of a principal market, in the most advantageous market for the asset or liability.

The Group must be able to access the principal market or the most advantageous market at the measurement date.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest. A fair value measurement of a non-financial asset takes into account a market participant’s ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

The Group uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs significant to the fair value measurement as a whole:

  • Level 1 – Quoted (unadjusted) market prices in active markets for identical assets or liabilities.
  • Level 2 – Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable.
  • Level 3 – Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly unobservable.

For assets and liabilities that are recognized in the financial statements on a recurring basis, the Group determines whether transfers have occurred between levels in the hierarchy by re-assessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.

Business combinations and goodwill

Business combinations are accounted for using the acquisition method. The cost of an acquisition is measured as the aggregate of the consideration transferred, measured at acquisition date fair value and the amount of any non-controlling interest in the acquiree. For each business combination, the Group elects whether it measures the non-controlling interest in the acquiree either at fair value or at the proportionate share of the acquiree’s identifiable net assets. Acquisition costs incurred are expensed and included in general and administrative expenses. When the Group acquires a business, it assesses the financial assets and liabilities assumed for appropriate classification and designation in accordance with the contractual terms, economic circumstances and pertinent conditions as at the acquisition date. This includes the separation of embedded derivatives in host contracts by the acquiree. If the business combination is achieved in stages, the acquisition date fair value of the acquirer’s previously held equity interest in the acquiree is re-measured to fair value at the acquisition date through profit or loss.

Any contingent consideration to be transferred by the acquirer will be recognized at fair value at the acquisition date. Subsequent changes to the fair value of the contingent consideration that is deemed to be an asset or liability will be recognized in accordance with IFRS 9 either in profit or loss or as a change to other comprehensive income. If the contingent consideration is classified as equity, it will not be remeasured. Subsequent settlement is accounted for within equity. In instances where the contingent consideration does not fall within the scope of IFRS 9, it is measured in accordance with the appropriate IFRS.

Goodwill is initially measured at cost being the excess of the aggregate of the consideration transferred and the amount recognized for the net identifiable assets acquired and liabilities assumed. If this consideration is lower than the fair value of the net assets of the subsidiary acquired, the difference is recognized in profit or loss.

After initial recognition, goodwill is measured at cost less any accumulated impairment losses. For the purpose of impairment testing, goodwill acquired in a business combination is, from the acquisition date, allocated to each of the Group’s cash-generating units that are expected to benefit from the combination, irrespective of whether other assets or liabilities of the acquiree are assigned to those units.

Where goodwill forms part of a cash-generating unit and part of the operation within that unit is disposed of, the goodwill associated with the operation disposed of is included in the carrying amount of the operation when determining the gain or loss on disposal of the operation. Goodwill disposed of in this circumstance is measured based on the relative values of the operation disposed of and the portion of the cash-generating unit retained.

Goodwill is reviewed for impairment annually or more frequently if events or changes in circumstances indicate that the carrying value may be impaired. At the acquisition date, any goodwill acquired is allocated to each of the cash-generating units expected to benefit from the business combination’s synergies. Impairment is determined by assessing the recoverable amount of the cash-generating unit to which the goodwill relates. Where the recoverable amount of the cash-generating unit is less than the carrying amount, an impairment loss is recognized, firstly on goodwill and then on the other assets.

Intangible assets

Intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is the fair value as at the date of acquisition. Following initial recognition, intangible assets are carried at costs less any accumulated amortization and any accumulated impairment losses. Internal development of software for internal use is recognized as intangible assets if the recognition criteria are met. Otherwise, the expenditure is reflected in the income statement in the year in which it is incurred. The useful lives of intangible assets are assessed to be either finite or indefinite.

Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method for an intangible with a finite useful life are reviewed at least at each financial year end. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are accounted for by changing the amortization period or method, as appropriate, and treated as changes in accounting estimates. The amortization expense on intangible assets with finite useful lives is recognized in the income statement in the expense category consistent with the function of the intangible asset.

Gains or losses arising from the derecognition of an intangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognized in the income statement when the asset is derecognized.

Research and development costs

Research costs are expensed as incurred. Development expenditures on an individual project are recognized as an intangible asset when the Group can demonstrate:

  • The technical feasibility of completing the intangible asset so that the asset will be available for use or sale
  • Its intention to complete and its ability to use or sell the asset
  • How the asset will generate future economic benefits
  • The availability of resources to complete the asset
  • The ability to measure reliably the expenditure during development
  • The ability to use the intangible asset generated

Amortization of the asset begins when development is complete and the asset is available for use. It is amortized over the period of expected future benefit.

The Group’s intangible assets consist of software and other intangible assets. Software is amortized on a straight-line basis over five to ten years whereas other intangible assets are amortized on a straight-line basis over five years.

Property, plant and equipment

Property, plant and equipment are stated at cost less accumulated depreciation and accumulated impairment losses. Such cost includes the costs of replacing part of the plant and equipment and borrowing costs for long-term construction projects, if the recognition criteria are met. Likewise, when a major inspection is performed, its cost is recognized in the carrying amount of the plant and equipment as a replacement, if the recognition criteria are satisfied. All other repair and maintenance costs are recognized as dwelling costs in the income statement.

Depreciation is calculated on a straight-line basis over the estimated useful life of the asset, as stated hereunder.

  • buildings (and leasehold improvements)

    10 to 50 years

  • machinery and equipment

    3 to 16 years

  • other

    3 to 5 years

An item of property, plant and equipment is derecognized upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on derecognizing the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the income statement in the year the asset is derecognized.

The assets’ residual values, useful lives and methods of depreciation are reviewed at each financial year end, and adjusted prospectively, if appropriate.

Borrowing costs

Borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalized as part of the cost of the respective assets. All other borrowing costs are expensed in the period they occur. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds.

Impairment of non-financial assets

The Group assesses at each reporting date whether there is an indication that an asset may be impaired. If any indication exists, or when annual impairment testing for an asset is required, the Group estimates the asset’s recoverable amount. An asset’s recoverable amount is the higher of an asset’s or cash-generating unit’s fair value less costs to sell and its value in use and is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets. When the carrying amount of an asset or cash-generating unit exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount.

Financial assets

Initial recognition and measurement

Financial assets are classified at initial recognition and subsequently measured at amortized cost, fair value through other comprehensive income or fair value through profit or loss.

The classification of financial assets at initial recognition depends on the financial asset’s contractual cash flow characteristics and the Group’s business model for managing them. With the exception of trade receivables that do not contain a significant financing component or for which the Group has applied the practical expedient, the Group initially measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss, transaction costs. Trade receivables that do not contain a significant financing component or for which the Group has applied the practical expedient are measured at the transaction price determined under IFRS 15.

In order for a financial asset to be classified and measured at amortized cost or fair value through other comprehensive income, it needs to give rise to cash flows that are “solely payments of principal and interest” on the principal amount outstanding. This assessment is referred to as the SPPI test and is performed at an instrument level.

The Group’s business model for managing financial assets refers to how it manages its financial assets in order to generate cash flows. The business model determines whether cash flows will result from collecting contractual cash flows, selling the financial assets, or both.

Subsequent measurement
The subsequent measurement of financial assets depends on their classification as described below:

Financial assets at amortized cost (debt instruments)
This category is most relevant to the Group. The Group’s financial assets at amortized cost mainly include trade receivables.

The Group measures financial assets at amortized cost if both of the following conditions are met:

  • the financial asset is held within a business model with the objective to hold financial assets in order to collect contractual cash flows; and
  • the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

Financial assets at amortized cost are subsequently measured using the effective interest method and are subject to impairment. Gains and losses are recognized in profit or loss when the asset is derecognized, modified or impaired.

Impairment of financial assets

The Group recognizes an allowance for expected credit losses for all debt instruments not held at fair value through profit or loss. Expected credit losses are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group expects to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from credit enhancements that are integral to the contractual terms.

Financial assets at amortized cost (debt instruments)
For trade receivables and contract assets, the Group applies a simplified approach in calculating expected credit losses. Therefore, the Group does not track changes in credit risk, but instead recognizes a loss allowance based on lifetime expected credit loss at each reporting date.

If, in a subsequent period, the amount of the impairment loss decreases and the decrease can be related objectively to an event occurring after the impairment was recognized, the previously recognized impairment loss is reversed, to the extent that the carrying value of the asset does not exceed its amortized cost.

The Group considers a financial asset to be in default when internal or external information indicates that the Group is unlikely to receive the outstanding contractual amounts in full before taking into account any credit enhancements held by the Group. A financial asset is written off when there is no reasonable expectation of recovering the contractual cash flows.

Inventories

Inventories are valued at the lower of cost and net realizable value.

Costs incurred in bringing each product to its present location and condition are accounted for as follows: Raw materials are stated at the purchase cost on a first in, first out basis. Finished goods and work-in-progress include costs of direct materials and labor and a proportion of manufacturing overhead based on normal operating capacity but excluding borrowing cost as the production does not require a substantial period of time.

Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale.

Other current assets

All other current assets are stated at the amounts at which they were acquired or incurred.

Cash and cash equivalents

Cash and cash equivalents in the statement of financial position and in the statement of cash flows comprise cash on hand and in banks and short-term deposits with an original maturity of three months or less.

Financial liabilities

Initial recognition and measurement
Financial liabilities are classified at initial recognition as financial liabilities at fair value through profit or loss, loans and borrowings and payables as appropriate.

All financial liabilities are recognized initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs. The Group’s financial liabilities include trade and other payables, loans and borrowings including bank overdrafts.

Subsequent measurement
The subsequent measurement of financial liabilities depends on their classification as described below:

Financial liabilities at fair value through profit or loss
This category comprised the contingent consideration payable following from the acquisition of Lonza Braine S.A. (renamed into PolyPeptide S.A.) on 3 January 2017 as further disclosed in Note 18. This contingent consideration was carried in the statement of financial position at fair value with changes in fair value recognized in the statement of income in the finance income or expense line. As at 31 December 2021, the contingent consideration was fully paid. The Group has no other financial liabilities being classified at fair value through profit or loss.

Other financial liabilities
All loans and borrowings, (trade) payables and other financial liabilities are initially recognized at fair value of the consideration received less directly attributable transaction costs. After initial recognition, these financial liabilities are subsequently measured at amortized cost using the effective interest rate method. Gains and losses are recognized in the income statement when the liabilities are derecognized as well as through the effective interest rate amortization process. Amortized cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the effective interest rate. The effective interest rate amortization is included in finance costs in the income statement.

Derecognition of financial assets and liabilities

Financial assets
A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is derecognized when:

  • the rights to receive cash flows from the asset have expired; or
  • the Group has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a “pass-through” arrangement and either (a) the Group has transferred substantially all the risks and rewards of the asset, or (b) the Group has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

When the Group has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, and has neither transferred nor retained substantially all the risks and rewards of the asset nor transferred control of the asset, the asset is recognized to the extent of the Group’s continued involvement in the asset. If there is an associated liability, the Group recognizes an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Group has retained.

Continued involvement that takes the form of a guarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the net of the carrying amount and the maximum amount of the consideration that the Group could be required to repay.

Financial liabilities
A financial liability is derecognized when the obligation under the liability is discharged or cancelled or expired. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as a derecognition of the original liability and the recognition of a new liability, and the difference in the respective carrying amounts is recognized in the income statement.

Provisions

Provisions are recognized when the Group has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Group expects some or all of a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when the reimbursement is virtually certain. The expense relating to any provision is presented in the income statement net of any reimbursement. If the effect of the time value of money is material, provisions are discounted using a current pre-tax discount rate that reflects, when appropriate, the risks specific to the liability. When discounting is used, the increase in the provision due to the passage of time is recognized as financial expenses in the income statement.

Pensions

The Group has insured contributory pension plans covering substantially all employees. Pension obligations are funded through annual premiums. The Group has defined benefit obligations to employees. The cost of providing benefits under the defined benefit plans is determined separately for each plan using the projected unit credit actuarial valuation method.

Remeasurements, comprising of actuarial gains and losses and the return on plan assets (excluding net interest), are recognized immediately in the consolidated statement of financial position with a corresponding debit or credit to retained earnings through other comprehensive income in the period in which they occur. Remeasurements are not reclassified to profit or loss in subsequent periods.

Past service costs are recognized in profit or loss on the earlier of:

  • the date of the plan amendment or curtailment; and
  • the date that the Group recognizes restructuring-related costs

Net interest is calculated by applying the discount rate to the net defined benefit liability or asset.

The Group recognizes the following changes in the net defined benefit obligation under cost of revenues and general and administrative expenses in the consolidated income statement:

  • Service costs comprising current service costs, past service costs, gains and losses on curtailments and non-routine settlements
  • Net interest expense or income

The defined benefit liability is the aggregate of the present value of the defined benefit obligation and the fair value of plan assets out of which the obligations are to be settled. Plan assets are assets that are held by a long-term employee benefit fund or qualifying insurance policies.

Plan assets are not available to the creditors of the Group, nor can they be paid directly to the Group. Fair value is based on market price information and in the case of quoted securities it is the published bid price.

Leases

All leases are accounted for by recognizing a right-of-use asset and a lease liability, except for:

  • Leases of low value assets; and
  • Leases with a term of 12 months or less.

Lease liabilities are measured at the present value of the contractual payments due to the lessor over the lease term, with the discount rate determined by reference to the rate inherent in the lease unless (as is typically the case) this is not readily determinable, in which case the Group’s incremental borrowing rate on commencement of the lease is used. Variable lease payments are only included in the measurement of the lease liability if they depend on an index or rate. In such cases, the initial measurement of the lease liability assumes that the variable element will remain unchanged throughout the lease term. Other variable lease payments are expensed in the period to which they relate.

On initial recognition, the carrying value of the lease liability also includes:

  • amounts expected to be payable under any residual value guarantee;
  • the exercise price of any purchase option granted in favor of the Group if it is reasonably certain to assess that option;
  • any penalties payable for terminating the lease, if the term of the lease has been estimated on the basis of a termination option being exercised.

Right-of-use assets are initially measured at the amount of the lease liability, reduced for any lease incentives received, and increased for:

  • lease payments made at or before commencement of the lease;
  • initial direct costs incurred; and
  • the amount of any provision recognized where the Group is contractually required to dismantle, remove or restore the leased assets.

Subsequent to initial measurement, lease liabilities are increased as a result of interest charged at a constant rate on the balance outstanding and are reduced for lease payments made. If the lease transfers ownership of the underlying asset by the end of the lease term or if the cost of the right-of-use asset reflects that a purchase option will be exercised, the right-of-use asset is depreciated from the commencement date to the end of the useful life of the underlying asset. Otherwise, the right-of-use asset is depreciated from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term.

When the Group revises its estimate of the term of any lease (because, for example, it re-assesses the probability of a lessee extension or termination option being exercised), it adjusts the carrying amount of the lease liability to reflect the revised net present value of future lease payments. The carrying amount of lease liabilities is similarly revised when the variable element of future lease payments dependent on a rate or an index is revised. In both cases, an equivalent adjustment is made to the carrying amount of the right-of-use asset, with the revised carrying amount being depreciated over the remaining (revised) lease term.

Other liabilities

All other liabilities are stated at the amounts at which they were acquired or incurred.

Cash flow statement

The cash flow statement is prepared according to the indirect method. Cash and cash equivalents comprise cash on hand and in banks and short-term deposits with an original maturity of three months or less. Interest and income tax cash flows are included in the cash flow from operating activities.

Future changes in accounting policies

The following standards, amendments to standards, and interpretations have been issued by the IASB and are mandatorily effective for reporting periods beginning 1 January 2023 or later. The Group has not early adopted any of these and does not expect them to have a significant impact on the consolidated financial statements:

  • IFRS 17 Insurance Contracts
  • Disclosure of Accounting Policies (Amendments to IAS 1 and IFRS Practice Statement 2)
  • Definition of Accounting Estimates (Amendments to IAS 8)
  • Deferred Tax related to Assets and Liabilities arising from a Single Transaction (Amendments to IAS 12)
  • Lease Liability in a Sale and Leaseback (Amendments to IFRS 16)
  • IAS 1 Presentation of Financial Statements (Amendment - Classification of Liabilities as Current or non-Current)
  • IAS 1 Presentation of Financial Statements (Amendment - Non-current Liabilities with Covenants)

Significant accounting judgments and estimates

The preparation of the Group’s consolidated financial statements requires management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the accompanying disclosures. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of assets or liabilities affected in future periods.

Estimates and assumptions

The key assumptions concerning the future and other key sources of estimation uncertainty at the reporting date, that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year, are described below. The Group based its assumptions and estimates on parameters available when the consolidated financial statements were prepared. Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising beyond the control of the Group. Such changes are reflected in the assumptions when they occur.

Impact of rising inflation and interest rates
Inflation and interest rates increased in 2022, spurred by the geopolitical tensions.
The increased interest rates primarily impacted the measurement of the defined benefit obligation at the reporting date since it is measured by discounting future cash flows to a net present value, using a discount rate that reflects the general interest rate level.
The increases in inflation resulted in increased energy and raw material costs, wages, etc., particularly leading to increased cost of sales recognized in the income statement.

Impairment of non-financial assets
The Group assesses whether there are any indicators for impairment for all non-financial assets at each reporting date and tests for impairment when there are indicators that the carrying amounts may not be recovered. When value in use calculations is undertaken, management must estimate the expected future cash flows from the asset or cash-generating unit and choose a suitable discount rate in order to calculate the present value of those cash flows (see Note 8, 9 and 10). Even though 2022 was characterized by a volatile macroeconomic environment as discussed above, the Group has not identified any indicators for impairment. No impairment losses of non-current assets have thus been recognized in 2022 (2021: no impairment losses).

Pension and other employment benefits
The cost of defined benefit pension plans is determined using actuarial calculations. The actuarial calculations involve making assumptions about discount rates, expected rates of return on assets, future salary increases, mortality rates and future pension increases. Due to the complexity of the valuation, the underlying assumptions and its long-term nature, a defined benefit obligation is highly sensitive to changes in these assumptions (see Note 16).

Deferred income tax assets
Deferred tax assets are recognized for all unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilized. Management’s judgement is required to determine the amount of deferred tax assets that can be recognized, based upon the likely timing and level of future taxable profits together with future tax planning strategies (see Note 5).

2 Segment information

Financial Report

2Segment information

PolyPeptide generates revenue that can be divided into the three business areas described in Note 3. The chief operating decision maker (i.e., the Executive Committee) reviews revenue generated within each business area but does not review results at this disaggregated level. The chief operating decision maker rather reviews the results of the Group as a whole to assess performance. This internal assessment of performance has not changed since the last annual financial statements of the Group. However, the definition of an operating segment according to IFRS 8 – Operating segments has been revisited, and it has been concluded that the three business areas should not be considered three separate operating segments since only revenue information for each area is reviewed by the chief operating decision maker. As a result, there is only one operating segment according to IFRS 8 – Operating segments.

The segment disclosures are thus provided in accordance with the requirements applicable for entities that have a single reportable segment.

Revenue from major customers (10% or more of total revenue)

In 2022, revenues of approximately kEUR 48,300 and kEUR 41,300 were derived from two customers.
In 2021, revenues of approximately kEUR 57,600 and kEUR 35,900 were derived from two customers.

Geographical areas

Shown below are the carrying amounts of non-current assets other than deferred income tax assets and other financial assets, broken down by location of the assets. Related additions to intangible assets and property, plant and equipment (PP&E) during the year and revenues generated from the location of the assets are shown as well.

2022 kEUR

USA

Europe & Asia

Total

 

 

 

 

Revenue

90,158

190,820

280,978

Additions to intangible assets and PP&E

20,850

62,135

82,985

Non-current assets, carrying amount

106,825

206,334

313,159

 

 

 

 

 

 

 

 

2021 kEUR

USA

Europe & Asia

Total

 

 

 

 

Revenue

89,887

192,239

282,126

Additions to intangible assets and PP&E

33,225

43,427

76,652

Non-current assets, carrying amount

90,094

159,616

249,710

3 Revenue and expenses

Financial Report

3Revenue and expenses

PolyPeptide generates revenue that can be divided into the three business areas described below:

Revenue by business area

kEUR

2022

2021

 

 

 

Custom Projects

140,044

167,006

Contract Manufacturing

110,753

89,600

Generics and Cosmetics

30,181

25,520

Total revenue

280,978

282,126

Custom Projects business area specializes in the manufacturing of custom research-grade peptides and oligonucleotides, in milligram, gram or pilot scale quantities, at predefined purity levels for use in pre-clinical and clinical development as well as for regulatory and scientific studies. Custom Projects also provides cGMP manufacturing services during the later phases of development. Revenue is allocated to Custom Projects for sales of products in the pre-clinical through clinical stage development (i.e., prior to commercial launch) as generally set out in master service agreements and/or the accompanying work / purchase orders.

Contract Manufacturing business area manufactures peptides for commercial stage peptide therapeutics, at scale, in commercial batches and in accordance with cGMP requirements. The Group's Contract Manufacturing services also include consultation for continuous improvement and process stabilization / optimization to support scale-up, process changes to support cost of goods sold enhancement, lifecycle management and extension as well as regulatory support. Revenue is allocated to Contract Manufacturing where production is related to the commercial supply of products, including the production of commercial generic products where we manufacture for the patent originator, as generally set out in master supply agreements and/or the accompanying work / purchase orders.

Generics and Cosmetics business area manufactures peptide-based generics for the human and veterinary market, produced on an industrial scale following cGMP guidelines. Generally, PolyPeptide’s generic products are off-patent and manufactured for numerous generic customers. The business area also includes revenue generated from the sale of peptides used in cosmetics, primarily for anti-aging applications. Revenue is allocated to Generics and Cosmetics for product sales to generics manufacturers and non-originators (i.e., not the original patent holder) as well as cosmetics sales, each as generally set out in nonproprietary master supply agreements and/or the accompanying work / purchase orders.

Revenue by geographical area

Revenue is attributed to the individual geographical area based on the invoice address of the respective customer.

kEUR

2022

2021

 

 

 

Americas

133,437

116,083

Europe

125,820

142,697

Asia Pacific

21,255

21,084

Others

466

2,262

Total revenue

280,978

282,126

Revenue from contracts with customers

2022 kEUR

API

Related services

Total

 

 

 

 

Timing of transfer of goods and services

 

 

 

Point in time

246,006

 

246,006

Over time

 

34,972

34,972

Total revenue

246,006

34,972

280,978

 

 

 

 

 

 

 

 

2021 kEUR

API

Related services

Total

 

 

 

 

Timing of transfer of goods and services

 

 

 

Point in time

255,422

 

255,422

Over time

 

26,704

26,704

Total revenue

255,422

26,704

282,126

Revenues from Active Pharmaceutical Ingredients (API) fully relate to the sale of goods and revenues from related services relate to the rendering of services. All revenues from contracts with customers classify as business-to-business.

Contract assets and contract liabilities

Contract assets

kEUR

2022

2021

 

 

 

As at 1 January

2,556

2,044

Transfer in the period from contract assets to trade receivables

-2,537

-2,044

Transfer of services to customers during the period where payment is not due as at the balance sheet date

2,652

2,532

Currency exchange differences

-11

24

As at 31 December

2,660

2,556

Contract liabilities

kEUR

2022

2021

 

 

 

As at 1 January

46,072

33,480

Amounts included in contract liabilities that were recognized as revenue during the period

-45,677

-33,480

Cash received in advance of performance and not recognized as revenue during the period

27,050

44,972

Currency exchange differences

93

1,100

As at 31 December

27,538

46,072

Contract assets and contract liabilities arise at each facility because cumulative payments received from customers at each balance sheet date do not necessarily equal the amount of revenue recognized on the contracts. Contract assets and liabilities are presented on the face of the consolidated statement of financial position.

Other operating income

kEUR

2022

2021

 

 

 

Research refund

1,683

1,190

Invoiced freight and insurance

413

292

Export incentives

90

17

Investment grants

80

115

Other

220

2,477

Total other operating income

2,486

4,091

The research refund of kEUR 1,683 (2021: kEUR 1,190) relates to a deduction on tax paid due to qualified research in chemistry. The investment grants of kEUR 80 (2021: kEUR 115) relates to improving air emission handling, etc.
US government loans waived of kEUR 2,370 in the context of the coronavirus pandemic are included as ‘Other’ in 2021.

Marketing and sales expenses

kEUR

2022

2021

 

 

 

Salaries and employee benefits

-3,122

-2,933

Marketing and promotion costs

-826

-428

Other

-957

-503

Total marketing and sales expenses

-4,905

-3,864

Research expenses

kEUR

2022

2021

 

 

 

Salaries and employee benefits

-790

-756

Other

-453

-651

Total research expenses

-1,243

-1,407

General and administrative expenses

kEUR

2022

2021

 

 

 

Salaries and employee benefits

-14,847

-16,935

Other staff expenses

-2,636

-1,951

Service fee Group-related company

-10

-147

Depreciation and amortization

-1,302

-1,590

Professional services

-4,884

-5,646

Insurance cost

-2,318

-1,801

IT services

-2,794

-2,263

Other

-6,932

-4,022

Total general and administrative expenses

-35,722

-34,355

IPO cost

The following IPO-related expenses are included within “General and administrative expenses” in the income statement:

kEUR

2022

2021

 

 

 

Consultancy services

0

-1,381

IPO cash bonus

0

-1,342

IPO share bonus

0

-2,998

Total IPO cost

0

-5,721

The IPO cash bonus amount relates to the bonus award made by the Group after the IPO to selected non-executives involved in the IPO process. The IPO share bonus amount relates to expenses incurred by the Group in relation to the shares awarded by Draupnir Holding B.V. in the IPO process. These expenses were fully reimbursed by Draupnir Holding B.V in H2 2021.

In addition, an amount of kEUR 4,652 relating to consultancy services, Swiss Federal Issue Stamp Tax and Bank Commissions was charged directly to the share premium reserve in 2021 in accordance with IAS 32.

Financial income

kEUR

2022

2021

 

 

 

Interest income due from third parties

9

8

Fair value decrease of contingent consideration (see Note 18)

0

645

Total financial income

9

653

Financial expenses

kEUR

2022

2021

 

 

 

Interest expenses due to third parties

-2,091

-2,127

Interest on contingent consideration (see Note 18)

0

-696

Foreign currency exchange losses

-1,627

-1,867

Other financial expenses

-1,331

-280

Total financial expenses

-5,049

-4,970

Staff costs and employee information

kEUR

2022

2021

 

Indirect

Direct

Indirect

Direct

 

 

 

 

 

Salaries and wages

-14,097

-68,722

-15,394

-56,672

Social charges

-2,695

-14,817

-3,062

-13,119

Pension costs

-1,967

-4,851

-2,168

-4,572

Total staff cost

-18,759

-88,390

-20,624

-74,363

An amount of kEUR 88,390 (2021: kEUR 74,363) relating to salaries and employee benefits has been included in cost of sales.

The average number of FTEs of the principal departments is as follows:

Average number of employees

 

2022

2021

 

 

 

Production

618

585

Marketing and sales

19

17

Research and development

176

154

General and administration

89

79

Quality control

130

112

Quality assurance

107

94

Total

1,139

1,041

Depreciation and amortization included in the income statement

Included in Cost of sales:

kEUR

2022

2021

 

 

 

Depreciation

-22,731

-17,231

Amortization

-2,030

-1,862

Total

-24,761

-19,093

Included in General and administrative expenses:

kEUR

2022

2021

 

 

 

Depreciation

-1,295

-1,090

Amortization

-7

-500

Total

-1,302

-1,590

4 Share-based payment

4Share-based payment

Share-based payment was introduced at the Group as part of the IPO on SIX Swiss Exchange on 29 April 2021.

The following equity-settled share-based payment arrangements are recognized in the consolidated financial statements:

Board of Directors

Members of the Board of Directors receive at least half of their fixed fees in shares, with the option to elect to be paid up to 100% of their fixed fee in shares. For Board members electing to receive more than 50% of their fixed fee in shares, the shares exceeding the 50% portion are granted at a discount of 20% to market price. The proportion between shares (in excess of 50%) and cash is selected by each Board member upon election at the annual general meeting and is fixed until next annual general meeting. The Board of Directors is compensated on a pro-rata basis for the period of service, even in the case of early termination or removal.

The fair value at grant date amounted to kEUR 799 (2021: kEUR 731), reflecting a measurement based on a total number of shares of 9,835 (2021: 12,540) and the price of EUR 81 (CHF 83) per share as at 26 April 2022 (2021: The initial public offering price of EUR 58 (CHF 64) per share).

All shares will be fully vested at the annual general meeting in April 2023. In 2022, a total amount of kEUR 809 (2021: kEUR 713) was recognized as “General and administrative expenses” in the income statement according to the principles of graded vesting in IFRS 2.

Chief Executive Officer

During the year ended 31 December 2021, the then current CEO of the Group, Raymond De Vré, was granted three separate share-based payment arrangements:

  • A one-time grant of shares at a value of kCHF 750, which was calculated at a 20% discount to the initial public offering price of CHF 64, as compensation for the loss of unvested options from his previous employer. The fair value at grant date amounted to kEUR 854, reflecting a measurement based on 14,648 number of shares and the initial public offering price of EUR 58 (CHF 64) per share. The grant includes a service condition of three years, one-third vesting each year as of 1 June (starting from 2022). The expenses are recognized in the income statement according to the principles of graded vesting in IFRS 2, resulting in an amount of kEUR 329 recognized as “General and administrative expenses” in 2022 (2021: kEUR 401).
  • A grant of shares at a value of kCHF 100 at 15% discount to the initial public offering price as compensation for his loss of variable payments for 2020 and 2021 from his previous employer. The fair value at grant date amounted to kEUR 107, reflecting a measurement based on 1,838 number of shares and the initial public offering price of EUR 58 (CHF 64) per share. The grant included a service condition of one year and vested on 1 July 2022. The expenses have been recognized on a straight-line basis in the income statement, resulting in an amount of kEUR 45 recognized as “General and administrative expenses” in 2022 (2021: kEUR 66).
  • During the second half of 2021, the Board of Directors adopted a Long-Term Incentive Plan (“LTIP”) for Executive Committee members and other members of senior management of the Group. Under this share-based incentive program, eligible participants will be awarded the contingent right to receive a certain number of shares in the future (“PSU(s)”) in the Company subject to, inter alia, continued employment and achievement of non-market performance targets. The actual number of PSUs that will eventually vest and be settled in shares depend on the RONOA and EPS performance of the Group over a three-year performance period.
      
    During the course of 2022, the Remuneration and Nomination Committee considered the expansion of the LTIP to the full executive Committee as well as other members of senior management. However, in light of PolyPeptide’s disappointing financial performance in 2022, the Remuneration and Nomination Committee ultimately recommended to the Board of Directors not to grant any long-term incentive awards in 2022. The then current CEO of the Group, Raymond De Vré, voluntarily agreed not to receive his annual target value 2022 for the allocation of PSUs as set out in his employment agreement. The Remuneration and Nomination Committee plans to revisit this topic during the course of 2023.

    For the year ended 31 December 2021, the only eligible participant in the LTIP was the then current CEO of the Group, Raymond De Vré. The PSUs were granted to Raymond De Vré on 29 November 2021. In accordance with IFRS 2, the maximum number of shares potentially vesting was used for the determination of the fair value of the grant. As a result, the fair value at grant date amounted to kEUR 1,241, reflecting a measurement based on 9,909 number of PSUs and the share price of PolyPeptide Group AG as of the grant date of EUR 125 (CHF 131). The vesting period ends 10 trading days after the shareholders approve the 2023 audited consolidated financial statements.

    In 2022, no expenses have been recognized in the income statement since it is expected that no shares from the 2021 grant will eventually vest. In 2021, an amount of kEUR 28 was recognized as “General and administrative expenses” in the income statement. This amount has been reversed in 2022.

IPO share bonus

For the year ended 31 December 2021, eligible members of the Board of Directors, the Executive Committee and certain other senior managers were granted a total of 51,434 number of shares upon the successful listing on SIX Swiss Exchange. The fair value at grant date amounted to kEUR 2,998 and was measured based on the initial public offering price of EUR 58 (CHF 64) per share.

Since all the shares vested immediately upon the listing, the full amount was recognized in the income statement in the year ended 31 December 2021 as “General and administrative expenses” (see Note 3). The amount was subsequently fully reimbursed by Draupnir Holding B.V., which was recognized directly in equity on “Other capital reserves” in the same period.

5 Taxation

Financial Report

5Taxation

Taxation includes local and foreign taxation. Major components of the tax expense were:

kEUR

2022

2021

 

 

 

Consolidated income statement

 

 

Current income tax charge

-2,705

-9,217

Deferred income tax charge

2,905

-3,373

Total income tax charge

200

-12,590

 

 

 

Consolidated statement of comprehensive income

 

 

Income tax directly charged to comprehensive income

-3,174

-354

Total income tax charge (credit)

-3,174

-354

Amounts recorded in the consolidated statement of comprehensive income relate to deferred income taxes on actuarial gains and losses on defined benefit plans as a result of IAS 19.

A reconciliation of the income tax charge applicable to profit from operating activities before income tax at the Swiss statutory income tax rate to income tax expense at the Company’s effective income tax rate for the years ended 31 December was as follows:

kEUR

2022

2021

 

 

 

Result before income taxes

7,567

59,848

 

 

 

At Swiss statutory income tax rate of 11.8 %

-895

-7,080

Different income tax rates of other countries

-1,148

-7,829

Non-deductible expenses and non-taxable income

-688

600

Non-capitalized tax losses

-382

-826

R&D tax credits

3,152

2,220

Effect of change in tax rates

209

185

Adjustments in respect of current income tax of previous year

-48

141

At an effective income tax rate of -2.7% (2021: 21.0%)

200

-12,590

The effective tax rate for 2022 is negative by -2.7%, which is due to the Group having a tax income, despite having a positive profit before tax result. The tax income is mainly due to recognized R&D tax credits in the USA, which are expected to be utilized in the future to reduce tax liabilities.

Non-capitalized tax losses are related to impairment of deferred tax assets on tax losses in Polypeptide Group AG. A deferred tax asset has not been recognized due to uncertainty on whether the tax loss will be utilized before a seven-year expiry limitation.

Income from R&D tax credits is related to US R&D tax credits. Included in the tax benefit recognized is a provision of kEUR 632 for the uncertainty about whether the claimed R&D tax credits will be sustained by the US tax authorities.

The deferred tax assets include an amount of kEUR 2,888 relating to US R&D tax credits that have been claimed but for which uncertainty exists about whether these will be sustained by the US tax authorities.

kEUR

2022

2021

 

 

 

Differences in carrying amount and fiscal valuation of assets and liabilities

4,232

7,846

Capitalized tax losses carried forward

4,054

2,409

Total deferred income tax assets

8,286

10,255

The deferred tax assets for losses carried forward relate to tax losses of PolyPeptide Laboratories Inc. (USA), PolyPeptide Laboratories France S.A.S. (France) and PolyPeptide SA (Belgium). The tax losses are expected to be offset against future taxable profits, which are expected to be realized within the foreseeable future.

The valuation of deferred tax assets for losses carried forward is based on management-approved medium-term budgets. Tax losses are expected to be utilized within five years.

The deferred tax asset for temporary differences mainly relates to a deferred tax asset for unutilized R&D tax credit in PolyPeptide Laboratories Inc. (USA), including provision for uncertainty about whether this can be sustained by the US tax authorities.

The Group has unrecognized tax loss carry-forwards available for losses incurred in various countries approximating kEUR 1,194,138 (2021: kEUR 10,842), of which kEUR 2,730 has no expiration date, kEUR 9,753 will expire by the end of 2028, and kEUR 1,181,655 will expire by the end of 2029. No deferred income tax asset has been recognized due to uncertainty with respect to available taxable profits in the future for these tax jurisdictions and the limitations imposed by tax legislation in order to utilize the tax losses.

The significant increase in unrecognized deferred tax losses is because of a tax deduction of equity in Polypeptide Group AG, which is permissible under Swiss Tax regulations. The tax deduction is calculated on the basis of the development of the share price of the Group.
The effect of this tax deduction and corresponding valuation allowance on the deferred tax asset has been reported through equity. As no net deferred tax asset is recognized for the tax loss generated by this tax deduction, there is no net tax effect reported in equity.

Deferred income tax liabilities as at 31 December relate to the following:

kEUR

2022

2021

 

 

 

Differences in carrying amount and fiscal valuation of assets and liabilities

1,878

1,106

Total deferred income tax liabilities

1,878

1,106

Differences in the carrying amount and tax values of assets and liabilities mainly relate to differences in valuation of Land & Buildings and Machinery & Equipment.

The deferred income tax charge relates to the following:

kEUR

2022

2021

 

 

 

Movement in deferred tax assets

616

-3,293

Movement in deferred tax liability

-772

-243

Translation differences

-113

-191

Total deferred income tax charge

-269

-3,727

kEUR

2022

2021

 

 

 

Deferred tax charge in income statement

2,905

-3,373

Deferred tax (credit) / charge in statement of comprehensive income

-3,174

-354

Total deferred income tax charge

-269

-3,727

Translation differences mainly relate to the Swedish Krona, Indian Rupee and US Dollar.

6 Shareholders' equity

Financial Report

6Shareholders' equity

Share capital

The parent company of the Group, PolyPeptide Group AG, was incorporated on 6 April 2021 with 30,000,000 shares with a nominal value of CHF 0.01 each, corresponding to a share capital of CHF 300,000.

The contribution of all the shares of PolyPeptide Laboratories Holding B.V. into PolyPeptide Group AG in exchange for one share increased the share capital by CHF 0.01.

In connection with the IPO, PolyPeptide Group AG further increased its initial share capital by issuing 3,125,000 shares with a nominal value of CHF 0.01 each, corresponding to an increase in its share capital of CHF 31,250. This transaction increased the share premium reserve by CHF 199,968,750.

There have been no changes to the share capital since the IPO. As a result, the share capital of PolyPeptide Group AG comprised 33,125,001 shares of CHF 0.01 each as at 31 December 2022. All shares are fully paid in.

Treasury shares

 

Number of shares

Average purchase/ transfer price (EUR)

% of number of shares in share capital

 

 

 

 

 

 

Own shares as at 1 January 2022

20,371

 

0.1%

 

Purchase

200,000

70

0.6%

 

Transfer

-21,175

71

-0.1%

 

Own shares as at 31 December 2022

199,196

 

0.6%

 

 

 

 

 

 

Own shares as at 1 January 2021

0

0

0.0%

 

Purchase

93,750

58

0.3%

 

Transfer

-73,379

58

-0.2%

 

Own shares as at 31 December 2021

20,371

 

0.1%

 

From March to July 2022, PolyPeptide Group AG purchased 200,000 own shares at the average price of EUR 70 to be held as treasury shares. 21,175 number of shares have been transferred to employees and Board members as part of their share-based remuneration during 2022 (2021: 73,379 number of shares were transferred to employees and Board members as part of their share-based remuneration, including as part of the IPO recognition bonus reimbursed by Draupnir Holding B.V.).

Cash distribution

On 26 April 2022, the shareholders of PolyPeptide Group AG approved at the Annual General Meeting to pay a cash distribution of CHF 0.3 per entitled share out of the foreign capital contribution reserves. Treasury shares held by the Company at the time of the cash distribution were not entitled to the cash distribution.

The distribution to shareholders of entitled shares totaled kEUR 9,671 (kCHF 9,916), which has been recognized against share premium in the consolidated financial statements.

No cash distribution was made in 2021.

7 Earnings per share

Financial Report

7Earnings per share

kEUR

2022

2021

 

 

 

 

 

Result for the year attributable to shareholders of PolyPeptide Group AG

7,767

47,258

 

 

 

 

 

Weighted average number of shares ('000)

33,125

32,123

 

Weighted average number of own shares ('000)

139

26

 

Weighted average number of outstanding shares ('000)

32,986

32,097

 

Dilution effect of share-based payment ('000)

18

27

 

Weighted average number of diluted shares ('000)

33,004

32,124

 

 

 

 

 

Earnings per share (EPS), basic

0.24

1.47

 

Earnings per share (EPS), diluted

0.24

1.47

 

Basic earnings per share has been calculated by dividing the result for the year attributable to the owners of PolyPeptide Group AG by the weighted average number of shares outstanding during the year. Treasury shares are not considered as outstanding shares.

Diluted earnings per share is calculated by dividing the result for the year attributable to the owners of PolyPeptide Group AG by the weighted average number of shares outstanding adjusted for all potentially dilutive shares. Dilutive shares arise from the share-based payment described in Note 4. 

8 Intangible assets

Financial Report

8Intangible assets

kEUR

Software

Other

Total

 

 

 

 

Acquisition value

 

 

 

Balance as at 1 January 2022

23,089

3,391

26,480

Additions

3,635

3,635

Disposals

-1,949

-1,949

Transfers

1,442

-1,442

Currency exchange differences

-75

-75

Balance as at 31 December 2022

28,091

28,091

 

 

 

 

Accumulated amortization and impairment losses

 

 

 

Balance as at 1 January 2022

-8,821

-3,391

-12,212

Amortization

-2,037

-2,037

Disposals

1,949

1,949

Transfers

-1,442

1,442

Currency exchange differences

74

74

Balance as at 31 December 2022

-12,226

-12,226

Carrying value as at 31 December 2022

15,865

15,865

kEUR

Software

Other

Total

 

 

 

 

Acquisition value

 

 

 

Balance as at 1 January 2021

18,876

9,978

28,854

Additions

4,110

4,110

Disposals

-6,604

-6,604

Transfers

101

101

Currency exchange differences

2

17

19

Balance as at 31 December 2021

23,089

3,391

26,480

 

 

 

 

Accumulated amortization and impairment losses

 

 

 

Balance as at 1 January 2021

-6,850

-9,448

-16,298

Amortization

-1,970

-392

-2,362

Disposals

6,465

6,465

Currency exchange differences

-1

-16

-17

Balance as at 31 December 2021

-8,821

-3,391

-12,212

Carrying value as at 31 December 2021

14,268

14,268

As at 31 December 2022, the carrying amount of software includes an amount of EUR 7.1 million (2021: EUR 4.3 million) that is still under construction. This software will be taken into use in subsequent periods and hence no amortization has been recognized over this software yet.

The Group assesses whether there are any indicators for impairment for all non-financial assets at each reporting date. If this is the case, the Group calculates the amount of impairment as the difference between the recoverable amount of the asset and its carrying value and recognizes the amount in the income statement. The Group has not identified any indicators for impairment during the year.

9 Property, plant and equipment

Financial Report

9Property, plant and equipment

kEUR

Land & Buildings

Machinery & Equipment

Assets under construction

Other operating assets

Total

 

 

 

 

 

 

Acquisition value

 

 

 

 

 

Balance as at 1 January 2022

87,666

170,545

87,397

434

346,042

Additions

659

253

78,324

114

79,350

Disposals

-3

-704

-3

-710

Transfers

34,878

33,085

-67,963

Currency exchange differences

816

-2,022

889

-317

Balance as at 31 December 2022

124,016

201,157

98,644

548

424,365

 

 

 

 

 

 

Accumulated depreciation and impairment losses

 

 

 

 

 

Balance as at 1 January 2022

-38,627

-90,584

-345

-129,556

Depreciation

-6,393

-14,088

-45

-20,526

Disposals

2

696

698

Currency exchange differences

-315

1,212

897

Balance as at 31 December 2022

-45,333

-102,764

-390

-148,487

Carrying value as at 31 December 2022

78,683

98,393

98,644

158

275,878

kEUR

Land & Buildings

Machinery & Equipment

Assets under construction

Other operating assets

Total

 

 

 

 

 

 

Acquisition value

 

 

 

 

 

Balance as at 1 January 2021

94,658

138,828

49,570

366

283,422

Additions

10

72,532

72,542

Disposals

-15,263

-325

-19

-1

-15,608

Transfers

5,812

30,082

-36,064

69

-101

Currency exchange differences

2,449

1,960

1,378

5,787

Balance as at 31 December 2021

87,666

170,545

87,397

434

346,042

 

 

 

 

 

 

Accumulated depreciation and impairment losses

 

 

 

 

 

Balance as at 1 January 2021

-48,875

-77,297

-320

-126,492

Depreciation

-3,890

-11,747

-26

-15,663

Disposals

15,263

221

1

15,485

Currency exchange differences

-1,125

-1,761

-2,886

Balance as at 31 December 2021

-38,627

-90,584

-345

-129,556

Carrying value as at 31 December 2021

49,039

79,961

87,397

89

216,486

The Group assesses whether there are any indicators for impairment for all non-financial assets at each reporting date. If this is the case, the Group calculates the amount of impairment as the difference between the recoverable amount of the asset and its carrying value and recognizes the amount in the income statement. The Group has not identified any indicators for impairment during the year.

The amount of borrowing costs capitalized during the year was nil (2021: nil). Other operating assets comprise office equipment.

As at 31 December 2022, the carrying amount of Land & Buildings includes an amount of approximately EUR 7.6 million (2021: EUR 8.9 million) for which the legal ownership is no longer with the Group due to the transaction with Monedula AB, as further disclosed in Note 18.

10 Leases

Financial Report

10Leases

Set out below are the carrying amounts of right-of-use assets recognized in the statement of financial position and the movements during the year:

kEUR

Buildings

Cars

Other equipment

Total

 

 

 

 

 

Cost of right-of-use assets

 

 

 

 

Balance as at 1 January 2022

17,999

2,272

3,863

24,134

Additions

1,054

730

1,434

3,218

Remeasurements

1,903

-11

1,892

Disposals

-215

-209

-424

Currency exchange differences

954

-29

-6

919

Balance as at 31 December 2022

21,910

2,747

5,082

29,739

 

 

 

 

 

Accumulated depreciation

 

 

 

 

Balance as at 1 January 2022

-3,056

-1,019

-1,103

-5,178

Depreciation

-1,783

-654

-1,063

-3,500

Disposals

215

210

425

Currency exchange differences

-96

21

5

-70

Balance as at 31 December 2022

-4,935

-1,437

-1,951

-8,323

Carrying value as at 31 December 2022

16,975

1,310

3,131

21,416

kEUR

Buildings

Cars

Other equipment

Total

 

 

 

 

 

Cost of right-of-use assets

 

 

 

 

Balance as at 1 January 2021

11,899

1,877

1,897

15,673

Additions

5,974

678

2,125

8,777

Remeasurements

-792

-8

-800

Disposals

-271

-174

-445

Currency exchange differences

918

-4

15

929

Balance as at 31 December 2021

17,999

2,272

3,863

24,134

 

 

 

 

 

Accumulated depreciation

 

 

 

 

Balance as at 1 January 2021

-1,701

-696

-398

-2,795

Depreciation

-1,204

-582

-872

-2,658

Disposals

255

174

429

Currency exchange differences

-151

4

-7

-154

Balance as at 31 December 2021

-3,056

-1,019

-1,103

-5,178

Carrying value as at 31 December 2021

14,943

1,253

2,760

18,956

Set out below are the carrying amounts of the lease liabilities recognized in the statement of financial position and the movements during the year:

kEUR

Buildings

Cars

Other equipment

Total

 

 

 

 

 

Lease liabilities

 

 

 

 

Balance as at 1 January 2022

14,232

1,270

2,503

18,005

Additions

1,054

730

1,419

3,203

Interest expenses

440

36

83

559

Remeasurements

1,918

-11

1,907

Lease payments

-1,293

-696

-1,265

-3,254

Currency exchange differences

821

-15

-8

798

Balance as at 31 December 2022

17,172

1,314

2,732

21,218

 

 

 

 

 

Lease liabilities

 

 

 

 

Balance as at 1 January 2021

9,732

1,200

1,501

12,433

Additions

5,472

678

2,124

8,274

Interest expenses

302

35

66

403

Remeasurements

-791

-8

-799

Lease payments

-1,206

-633

-1,200

-3,039

Currency exchange differences

723

-2

12

733

Balance as at 31 December 2021

14,232

1,270

2,503

18,005

The maturity of the total undiscounted lease liability as at 31 December is disclosed in Note 23.

The following amounts are recognized in the income statement:

kEUR

2022

2021

 

 

 

Depreciation expense of right-of-use assets

3,500

2,658

Interest expense on lease liabilities

559

403

Variable lease payments not included in the lease liabilities

244

21

Short-term leases (included in G&A expenses)

508

433

Leases of low-value assets (included in G&A expenses)

671

624

Total amount recognized in the income statement

5,482

4,139

The Group had total cash outflows for leases of kEUR 4,677 in 2022 (2021: kEUR 4,117).
The total lease liability of the Group mainly relates to leases of buildings in Torrance, USA. The remaining lease liability largely consists of machinery and company cars in various Group companies, primarily having fixed monthly lease payments.

11 Investments in subsidiaries

Financial Report

11Investments in subsidiaries

The consolidated financial statements include the financial statements of the Company and the subsidiaries listed below. Details of investments in subsidiaries as at 31 December are as follows:

Name

Location

Percentage of ownership

 

 

2022

2021

 

 

 

 

Polypeptide Laboratories Holding (PPL) AB

Limhamn, Sweden

100%

100%

Polypeptide Laboratories (Sweden) AB

Limhamn, Sweden

100%

100%

PolyPeptide SA

Braine-l’Alleud, Belgium

100%

100%

PolyPeptide Laboratories France S.A.S.

Strasbourg, France

100%

100%

PolyPeptide Laboratories Inc.

Torrance, CA, USA

100%

100%

PolyPeptide Laboratories San Diego, LLC 1

San Diego, CA, USA

100%

100%

PolyPeptide Laboratories Pvt. Ltd.

Ambernath (East), India

100%

100%

PolyPeptide Laboratories A/S 2

Hillerød, Denmark

100%

100%

PolyPeptide Laboratories GmbH 3

Hamburg, Germany

0%

100%

1 PolyPeptide Laboratories San Diego, LLC is a wholly owned subsidiary of PolyPeptide Laboratories Inc.

2 PolyPeptide Laboratories A/S is a dormant company.

3 During 2022, PolyPeptide Laboratories GmbH was merged into Polypeptide Laboratories Holding (PPL) AB.

Percentage of voting shares is equal to percentage of ownership.

12 Inventories

Financial Report

12Inventories

kEUR

2022

2021

 

 

 

Raw materials and supplies

61,435

38,757

Work in progress

51,417

51,211

Finished goods

32,221

23,033

Balance as at 31 December

145,073

113,001

Raw materials that are expired or that are no longer used in production, and finished goods for which no future sales are expected, are fully written off at the balance sheet date. Finished goods that are expected to be sold after retesting are written off for the expected loss during this retesting. The estimated loss is approximately 10% of the original weight of the batch.

Costs of inventories recognized in cost of sales in the income statement during the financial year amounted to kEUR  85,952 (2021: kEUR 65,998).

Provisions for obsolete stock amounted to EUR 39,916 as at 31 December 2022 (2021: kEUR 27,206). Inventory write-offs recognized in cost of sales in the income statement during the financial year 2022 amounted to kEUR 7,154, mainly due to inventory write-offs in France and Sweden (2021: kEUR 5,439, mainly due to inventory write-offs in Belgium and Sweden).

13 Trade receivables

Financial Report

13Trade receivables

kEUR

2022

2021

 

 

 

Trade receivables

46,486

65,233

Balance as at 31 December

46,486

65,233

Trade receivables are non-interest bearing and are generally on 30-90 day terms.

The aging analysis of trade receivables is as follows:

kEUR

Total

< 30 days

30-60 days

60-90 days

90-120 days

> 120 days

31 December 2022

46,486

42,069

1,349

1,667

832

569

31 December 2021

65,233

60,948

3,132

120

207

826

The Group applies the IFRS 9 simplified approach to measuring expected credit losses using a lifetime expected credit loss provision for trade receivables and contract assets. To measure expected credit losses on a collective basis, trade receivables and contract assets are grouped based on similar credit risk and aging. The contract assets have similar risk characteristics to the trade receivables for similar types of contracts.

A significant part of the outstanding accounts receivable balance relates to large reputable pharmaceutical companies with no known history of write-offs. The expected credit loss for these large pharmaceutical companies is estimated at nil. For smaller outstanding debtors, the expected loss rates are based on the Group’s historical credit losses experienced over the three-year period prior to the period end. These historical loss rates are then adjusted for current and forward-looking information on macroeconomic factors affecting the Group’s customers.

Movements in the bad debt allowance for trade receivables are as follows:

kEUR

2022

2021

 

 

 

Balance as at 1 January

-131

-141

Increase in bad debt allowance

-55

0

Receivable written-off during the year as uncollectible

8

0

Unused amounts reversed

0

22

Currency exchange difference

-9

-12

Balance as at 31 December

-187

-131

14 Other current assets

Financial Report

14Other current assets

kEUR

2022

2021

 

 

 

Prepaid expenses

5,003

4,749

VAT receivable

5,892

4,436

Other

1,555

1,629

Balance as at 31 December

12,450

10,814

Other current assets are non-interest-bearing and are normally settled on 60-day terms.

15 Cash and cash equivalents

Financial Report

15Cash and cash equivalents

For the purpose of the Consolidated Statement of Cash Flows, cash and cash equivalents comprise the following as at 31 December of each year:

kEUR

2022

2021

 

 

 

Cash and cash equivalents

37,528

136,303

Balance as at 31 December

37,528

136,303

The balance as at 31 December 2021 includes a term deposit of kCHF 92,500 (kEUR 89,540), which was fixed until 3 February 2022.

For the purpose of the Consolidated Statement of Cash Flows, changes in liabilities arising from financing activities for the years were as follows:

kEUR

Non-current interest bearing loans and borrowings

Non-current other financial liabilities

Lease liabilities

Current other financial liabilities

 

 

 

 

 

Balance as at 1 January 2022

10,302

18,005

1,145

 

 

 

 

 

Cash flows

 

-3,254

-1,145

 

 

 

 

 

Non-cash flows

 

 

 

 

New lease liabilities

3,203

Remeasurements

523

1,907

Accrued interest

611

559

Fair value loss/(gain)

Government loans waived

Transfer from non-current to current

-1,096

1,096

Currency exchange differences

-929

798

Balance as 31 December 2022

9,410

21,218

1,096

kEUR

Non-current interest bearing loans and borrowings

Non-current other financial liabilities

Lease liabilities

Current other financial liabilities

 

 

 

 

 

Balance as at 1 January 2021

25,000

16,697

12,433

10,199

 

 

 

 

 

Cash flows

-25,000

-5,890

-3,039

-7,844

 

 

 

 

 

Non-cash flows

 

 

 

 

New lease liabilities

8,274

Remeasurements

217

-799

Accrued interest

1,335

403

Fair value loss/(gain)

-645

Government loans waived

-2,355

Transfer from non-current to current

-1,145

1,145

Currency exchange differences

-267

733

Balance as 31 December 2021

10,302

18,005

1,145

16 Pensions

Financial Report

16Pensions

Provision for pensions

The Group participates in local pension plans in countries in which they operate. There are principally two types of pension plans:

  • Defined contribution plans, where the Group’s only obligation is to pay a pension premium to a fund or insurance company on behalf of the employee. Contributions to defined contribution pension schemes are charged to the consolidated income statement in the year to which they relate.
  • Defined benefit plans, where the Group’s undertaking is to provide pension benefits related to services rendered based on final salary levels. This plan is managed by recording the total accumulated pension obligation as a provision on the statement of financial position with no assigned plan assets. This method is used in Sweden, France, Belgium, India and Switzerland.

In PolyPeptide Laboratories (Sweden) AB and PolyPeptide S.A., the total pension benefits are mixed plans. Some parts are defined contribution-type plans and some parts are defined benefit-type plans. For each of the defined benefit plans, no trust is established and the full liability is recorded in the statement of financial position with compulsory insurance coverage. The Swedish actuarial determined liability is calculated by a third-party institution, the Pension Registration Institute (PRI), using assumptions defined by the company. PRI also administrates the pension payments to employees, which are subsequently charged to the company. The Belgium fund is outsourced to an insurance company called AXA Insurance. All funds requested to cover the year are called by and paid to the insurance company. Additionally, an actuarial evaluation is performed under IFRS rules in order to determine the liability. This computation is performed by a third-party institution.

PolyPeptide Laboratories France SAS has, in accordance with French law, accounted for a lump sum to be paid to employees upon retirement. In the consolidated numbers, IAS 19 is followed regarding the accounting treatment of pensions. The French actuarial determined liability is calculated by a third-party institution, using assumptions defined by the company.

Movement in the provision for pensions for the years was as follows:

kEUR

2022

2021

 

 

 

Defined benefit obligation as at 1 January

38,981

39,128

Interest costs

547

342

Current service costs

3,279

3,094

Net actuarial (gain)/losses through other comprehensive income

-12,287

-1,330

Benefits paid

-2,281

-1,828

Currency exchange difference

-1,602

-425

Balance as at 31 December

26,637

38,981

Pension expenses reflected in the income statement:

kEUR

2022

2021

 

 

 

Current service costs

-3,279

-3,094

Interest costs

-547

-342

Net benefit expenses

-3,826

-3,436

 

 

 

Defined contribution pension expenses

-3,539

-3,646

Total pension expenses

-7,365

-7,082

The principal assumptions used in determining pension obligations are shown hereunder:

kEUR

2022

2021

 

Belgium

Sweden

Belgium

Sweden

Discount rate

3.80%

3.70%

0.90%

1.90%

Future salary increases

3.87%

2.70%

3.45%

2.90%

Future pension increases

2.20%

2.70%

1.80%

2.20%

Long-term assumptions inflation

2.20%

2.00%

1.80%

2.20%

The forecasted defined benefit obligation for the year 2023 is assessed at kEUR 27,423 (2022: kEUR 40,529).

Sensitivity to changes in assumptions

Changes in the assumptions will impact the defined benefit pension obligation as at 31 December 2022 as follows:

kEUR

0.5%

(0.5%)

 

 

 

Discount rate (increase 0.5% / decrease 0.5%)

-2,230

2,473

Future salary increases (increase 0.5% / decrease 0.5%)

1,625

-1,478

Long-term assumption inflation (increase 0.5% / decrease 0.5%)

1,433

-1,341

17 Provisions

Financial Report

17Provisions

kEUR

2022

2021

 

 

 

Provision for pension taxes

739

2,618

Provision for product warranty

0

293

Provision for restoration costs

1,600

1,507

Provision for litigation

75

94

Other provisions

62

56

Balance as at 31 December

2,476

4,568

The provision for pension taxes relates to wage taxes of 24.26% on Swedish pension premiums.

The provision for product warranty in 2021 related to a rare undetected equipment issue, which impacted multiple batches produced for one customer in 2020. It was reversed during 2022 since it was no longer more likely than not that a present obligation existed at the end of the year.

The provision for restoration costs relates to the requirement to return leased properties of the Torrance facility into the conditions required by the terms and conditions of the lease agreements.

The provision for litigation relates to labor law claims from former employees.

Movement of the provision for the years was as follows:

kEUR

2022

2021

 

 

 

Balance as at 1 January

4,568

4,312

Utilization

-46

0

Additions through profit or loss

36

281

Reversals through profit or loss

-704

-486

(Release)/additions through other comprehensive income

-1,239

0

Other movements

0

443

Currency exchange differences

-139

18

Balance as at 31 December

2,476

4,568

18 Other financial liabilities

Financial Report

18Other financial liabilities

kEUR

2022

2021

 

 

 

Financial liability to Monedula AB

10,506

11,447

Total other financial liabilities as at 31 December

10,506

11,447

 

 

 

Non-current other financial liabilities

9,410

10,302

Current other financial liabilities

1,096

1,145

Total other financial liabilities as at 31 December

10,506

11,447

Financial liability to Monedula AB

In December 2019, PolyPeptide Laboratories (Sweden) AB sold all its shares in PolyPeptide Fastighets AB to related party Draupnir Holding B.V.
PolyPeptide Fastighets AB was subsequently renamed into Monedula AB.

Monedula AB is the owner of the premises that are leased by PolyPeptide Laboratories (Sweden) AB. At transaction date, PolyPeptide Laboratories (Sweden) AB and Monedula AB also extended the existing lease agreement to 31 December 2035.

Although the legal ownership of the premises was transferred to the buyer, management concluded that the transfer of the premises did not satisfy the requirements of IFRS 15 and hence that the transaction should not be accounted for as a sale of the asset. Therefore, the carrying value of the premises as at the transaction date remained on the consolidated statement of financial position of the Group. The consideration received for the premises in the amount of SEK 124.8 million (kEUR 11,947) was recognized as other financial liability accounted for in accordance with IFRS 9 as prescribed in IFRS 16.103(a).

The financial liability is currently measured at amortized cost using an effective interest rate of 5.57% (2021: 5.57%). The financial liability matures on 31 December 2035 and will be settled with future lease terms payable to Monedula AB. The total carrying value of the liability as at 31 December 2022 amounts to SEK 116.8 million (kEUR 10,506), of which SEK 12.2 million (kEUR 1,096) is presented as current financial liability. The total carrying value of the liability as at 31 December 2021 amounted to SEK 117.3 million (kEUR 11,447), of which SEK 11.7 million (kEUR 1,145) was presented as current financial liability.

Contingent consideration due to acquisition of a subsidiary

The contingent consideration related to the acquisition of Lonza Braine S.A. (renamed into PolyPeptide SA) on 3 November 2017.

A reconciliation of the contingent consideration for the years is as follows:

kEUR

2022

2021

 

 

 

Balance as at 1 January

0

12,497

Payment of contingent liability

0

-12,548

Fair value adjustment of contingent consideration (see Note 3)

0

-645

Accrued interest on contingent consideration (see Note 3)

0

696

Total contingent consideration as at 31 December

0

0

 

 

 

Non-current contingent consideration

0

0

Current contingent consideration

0

0

Total contingent consideration as at 31 December

0

0

The contingent consideration was fully paid as at the end of 2021.

19 Short-term borrowings from banks

Financial Report

19Short-term borrowings from banks

As at 31 December 2022, the Group had been granted multiple overdraft facilities for a total amount of kEUR 26,200 (2021: kEUR 26,200).

An amount of kEUR 25,000 was granted by Danske Bank (2021: kEUR 25,000), of which nil was drawn as at 31 December 2022 (2021: nil). The interest rate on the DANSKE Bank facility amounts to DANSKE BOR plus a margin of 0.80% (2021: 0.80%) on the amounts drawn.

The remaining kEUR 1,200 was granted by ING Bank (2021: kEUR 1,200), of which nil was drawn as at 31 December 2022 (2021: nil). The interest rate on the ING Bank credit facility amounts to EURIBOR plus a margin of 1.5% (2021: 1.5%) on the amounts drawn.

20 Trade payables and other current liabilities

Financial Report

20Trade payables and other current liabilities

kEUR

2022

2021

 

 

 

Trade payables

45,933

28,481

Total trade payables

45,933

28,481

 

 

 

Taxes and social securities

4,786

3,575

Government grants

0

54

Accrued expenses

12,407

16,901

Other

659

674

Total other current liabilities

17,852

21,204

Trade payables and other current liabilities are non-interest-bearing.

21 Contingent liabilities and guarantees

Financial Report

21Contingent liabilities and guarantees

Limited Partnership Investment
In November 2021, the Group entered into a limited partnership agreement with a commitment to invest a maximum amount of kUSD 30,000. An amount of kUSD 3,000 has been paid as at 31 December 2022 and recognized in the balance sheet as “Other financial assets”. As a result, the Group has a contingent liability of kUSD 27,000 (kEUR 25,315). If the general partner of the limited partnership makes an additional capital call, the Group would be obliged to pay the amount within ten business days.

Guarantee pension fund
All members of the PRI Pensionsgaranti, the issuer of the definied benefit plan in Sweden, are subject to a mutual liability. This liability would only be invoked in the event that PRI Pensionsgaranti has consumed all its assets. The mutual liability of the Group is limited to a maximum of 2% of the Group's individual pension liability with PRI Pensionsgaranti. As such, the Group has a contingent liability of kEUR 225 as at 31 December 2022 (2021: kEUR 182), for which it has issued a guarantee to PRI Pensionsgaranti.

22 Related parties

Financial Report

22Related parties

The following transactions have been entered into with related parties:

2022 kEUR

Income from related parties

Purchases from related parties

Amounts due from related parties

Amounts due to related parties

 

 

 

 

 

Entity with control over the company

 

 

 

 

Draupnir Holding B.V. 1

 

 

 

 

 

Other related entities

 

 

 

 

Thalamus

-167

-304

Ferring Group

41,300

-38

5,918

-4

Monedula AB

191

-1,556

-10,506

Amzell B.V.

172

Amring Pharmaceuticals Inc

Bazell Pharma AG

SVAR Life Science AB

166

Nordic Pharma Ltd.

-7

1 A cash distribution of CHF 0.3 per entitled share was approved by the General Meeting in April 2022. This resulted in a cash distribution of kEUR 5,363 to Draupnir Holding B.V. in May 2022.

2021 kEUR

Income from related parties

Purchases from related parties

Amounts due from related parties

Amounts due to related parties

 

 

 

 

 

Entity with control over the company

 

 

 

 

Draupnir Holding B.V.

6,794

-221

 

 

 

 

 

Other related entities

 

 

 

 

Thalamus

-167

-404

Ferring Group

36,169

-3

2,999

Monedula AB

355

-1,224

438

-11,447

Amzell B.V.

166

Amring Pharmaceuticals Inc

9

Bazell Pharma AG

1

SVAR Life Science AB

79

Nordic Pharma Ltd.

-9

All disclosed related parties are either related through the Esperante Investments S.à r.l. ownership structure or through managerial control. Esperante Investments S.à r.l. is a higher parent company of our majority shareholder Draupnir Holding B.V.

Income from Draupnir Holding B.V. primarily relates to reimbursement of IPO recognition bonuses. Purchases from Draupnir Holding B.V. relate to service and insurance fees.

Purchases from and amounts due to Thalamus AB relate to rental of premises.

Income from the Ferring Group and amounts due from the Ferring Group relate to sale of goods.

Purchases from Monedula AB relate to the lease of premises. Income and amounts due from Monedula relate to property management fees and recharged improvements to the premises. Amounts due to Monedula AB relate to the financial liability as disclosed in Note 18.

Income from and amounts due from Amzell B.V. relate to sale of goods.

Income from SVAR Life Science AB relates to sale of goods.

During the year, no provisions for doubtful debt and no write-offs on receivables from related parties were recognized (2021: nil). No guarantees were given or received for any outstanding related party balances (2021: nil).

Transactions with key management personnel

Compensation of key management personnel of the Group:

kEUR

2022

2021

 

 

 

Salaries and short-term benefits

3,112

3,454

Post-employment benefits

292

279

Share-based payment expense

1,155

4,206

Total transactions with key management

4,559

7,939

Reference is made to Note 4 for further details on the share-based payment expense.
Key management personnel are considered all members of the Executive Committee and the Board of Directors.

23 Financial risk management objectives and policies

Financial Report

23Financial risk management objectives and policies

The Group’s principal financial instruments comprise lease liabilities, other financial assets and liabilities and cash. The main purpose of these financial instruments is to raise finance for the Group’s operations. The Group has various other financial instruments such as trade debtors and trade creditors and other current assets and liabilities that arise directly from its operations. It is the Group’s policy that no trading in financial instruments shall be undertaken. The main risks arising from the Group’s financial instruments are market risk, credit risk and liquidity risk

Market risk

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices. Market prices comprise two types of risk: interest rate risk and foreign currency risk. The sensitivity analyses in the following sections relate to the position as at 31 December 2022 and 2021. The sensitivity analyses have been prepared on the basis that the amount of net debt, the ratio of fixed to floating interest rates of the debt and the proportion of financial instruments in foreign currencies are all constant. The analyses exclude the impact of movements in market variables on the carrying value of pension and other post-retirement obligations, provisions and on the non-financial assets and liabilities of foreign operations.

The following assumptions have been made in calculating the sensitivity analyses:

Interest rate risk:

  • The sensitivity of the profit before tax is the effect of the assumed changes in interest rates on the net interest income for one year, based on the floating rate non-trading financial assets and financial liabilities held at the balance sheet date.

Foreign currency risk:

  • The sensitivity of the profit before tax is the effect of the assumed changes in currency rates of third-party financial instruments in a foreign currency other than the functional currency of the respective subsidiaries.

Interest rate risk

Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Group is exposed to interest rate cash flow risk as interest-bearing loans and borrowings have been granted at fixed and variable interest rates. Revision of the fixed interest rate is possible at renewal of the liability. The Group decides whether to enter into fixed or variable interest contract based on the most favorable conditions at the time of entering into the contract. The Group does not enter into derivatives to hedge interest rate risks

The table below demonstrates the sensitivity to a reasonable possible change in interest rates, with all other variables held constant, of the Group’s profit before tax (through the impact on floating rate borrowings).

Effect on profit before tax

kEUR

2022

2021

 

 

 

Change in interest rates

 

 

Increase in basis points:

 

 

15

56

-134

20

75

-179

 

 

 

Decrease in basis points:

 

 

(10)

-38

90

(15)

-56

134

In 2021, the Group had bank deposits with a negative interest rate. For 2021, an increase in the table above thus reflects the impact on the Group’s profit before tax if the negative interest rate increased to an even more negative level, whereas a decrease reflects the impact on the Group’s profit before tax if the negative interest rate decreased to a less negative level.
In 2022, the interest rates on the Group’s bank deposits were positive. As a result, the amounts in the table for 2022 are shown with an opposite sign compared to 2021.

Foreign currency risk

Due to operations in Sweden, India, Switzerland and the United States of America, the Group’s statement of financial position is affected by movements in the foreign exchange rates. The Group does not enter into derivative transactions. The Group has also transactional currency exposures, such exposures arising from sales or purchases in currencies other than the currency of the operating subsidiaries. As the volumes of these transactions are relatively low compared to the total volume, the foreign currency risk exposure is considered low.

The Group has no currency exposure on financial instruments as all third-party interest-bearing loans and borrowings are due in the functional currency of the respective subsidiary that has subscribed to the interest-bearing loans and borrowings. The trade debtors, trade creditors and other financial liabilities are primarily stated in functional currency of the operations.

The table below demonstrates the sensitivity to a reasonable possible change in currencies, with all other variables held constant, of the Group’s profit before tax and the Group’s equity (through the impact on non-functional currencies).

kEUR

Effect on profit before tax

Effect on equity

 

2022

2021

2022

2021

 

 

 

 

 

Change in currency percentage

 

 

 

 

5%

-70

-2,243

-16,672

-13,904

(5%)

77

2,479

18,427

15,368

Credit risk

Credit risk is the risk that a counterparty will not meet its obligations under a financial instrument or customer contract, leading to a financial loss. Concentrations of credit risk exist when changes in economic, industry or geographic factors similarly affect groups of counter-parties whose aggregate credit exposure is significant in relation to the Group’s total credit exposure. The Group has no significant credit risks, other than those that have already been allowed for, nor any concentrations of credit with a single customer or in an industry or geographical region that carries an unusually high credit risk.

Credit risks relating to the trade receivables and cash balances are monitored regularly. Clients are assessed according to Group criteria prior to entering into agreements. The maximum exposure to credit risk at the reporting date is the carrying value of each class of financial assets mentioned in Notes 13, 14 and 15.

Liquidity risk

The Group monitors its risk to a shortage of funds using a cash flow forecast model. This model considers the maturity of both its non-current and current assets (trade receivables and other financial assets) and projected cash flows from operations. The Group’s objective is to maintain a balance between continuity of funding and flexibility through the use of bank overdrafts, bank loans and funding from and to other entities within the Group. Payments will be covered out of cash flow from operating activities, cash and facilities available.

The table below summarizes the maturity profile of the Group’s financial liabilities at 31 December of each year based on contractual undiscounted payments.

kEUR

Less than 1 year

1-5 years

More than 5 years

Total

 

 

 

 

 

Year ended 2022

 

 

 

 

Other financial liabilities

-1,096

-4,385

-5,025

-10,506

Lease liabilities

-3,588

-9,522

-10,825

-23,935

Trade payables

-45,933

-45,933

Other current liabilities

-2,522

-2,522

Balance as at 31 December 2022

-53,139

-13,907

-15,850

-82,896

 

 

 

 

 

 

 

 

 

 

kEUR

Less than 1 year

1-5 years

More than 5 years

Total

 

 

 

 

 

Year ended 2021

 

 

 

 

Other financial liabilities

-1,174

-4,694

-10,366

-16,234

Lease liabilities

-3,083

-8,099

-9,466

-20,648

Trade payables

-28,481

-28,481

Other current liabilities

-6,197

-6,197

Balance as at 31 December 2021

-38,935

-12,793

-19,832

-71,560

Capital management

The primary objective of the Group’s capital management is to maintain sound capital ratios in order to support its business and maximize shareholder value. The Group manages its capital structure and makes adjustments to it, in light of changes in economic conditions. To maintain or adjust the capital structure, the Group may adjust the dividend payment to shareholders, return capital to shareholders or issue new shares. No changes were made to the objectives, policies or processes during the years ended 31 December 2022 and 31 December 2021.

The Group monitors capital using shareholder equity ratio, which is the total shareholder equity divided by total equity and liabilities, based on the consolidated financial statements. The Group has no formally approved ratio range but considers a ratio above 25% as being sound. 

The table below shows the shareholder equity ratio for the years 2022 and 2021.

kEUR

2022

2021

 

 

 

Total shareholder equity

421,677

421,173

Total equity and liabilities

575,782

595,038

Equity ratio as at 31 December

73.2%

70.8%

24 Financial instruments

Financial Report

24Financial instruments

Fair values

In view of their short-term nature, the fair values of financial instruments of cash, trade receivables and payables, and short-term liabilities approximate their carrying amounts. All financial assets and liabilities are measured at amortized cost except for the investment in a limited partnership (see Note 21), which is measured at fair value through profit or loss.

Set out below is a comparison by category of carrying amounts and fair values of all of the Group’s financial non-current instruments that are carried in the financial statements.

kEUR

Carrying value

Fair value

 

2022

2021

2022

2021

Financial assets

 

 

 

 

Other financial assets

2,767

3,467

2,575

4,148

 

 

 

 

 

Financial liabilities

 

 

 

 

Other financial liabilities

-10,506

-11,447

-10,506

-11,447

Fair value hierarchy

Quantitative disclosures of the Group’s financial instruments in the fair value measurement hierarchy (see Note 1) are as follows:

kEUR

Level 1

Level 2

Level 3

 

 

 

 

As at 31 December 2022

 

 

 

Other financial assets

126

2,449

Other financial liabilities

-10,506

 

 

 

 

 

 

 

 

As at 31 December 2021

 

 

 

Other financial assets

1,295

204

2,649

Other financial liabilities

-11,447

The fair value of the financial assets and liabilities is included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale. Level 1 inputs include the publicly listed share price of PolyPeptide Group AG. Level 2 inputs include the discounted cash flow method using a discount rate that reflects the issuer’s borrowing rate as at the end of the reporting period. Level 3 inputs include unobservable inputs that reflect the assumptions that market participants would use when pricing the asset, including assumptions about risk (applicable for 2022), as well as the price paid by the Group for the financial asset just before the balance sheet date (applicable for 2021).

The own non-performance risk as at 31 December 2022 was assessed and considered to be insignificant.

25 Subsequent events

Financial Report

25Subsequent events

There have been no significant events subsequent to the balance sheet date that would require additional disclosure in the consolidated financial statements.

The consolidated financial statements for 2022 were approved for issue by the Board of Directors on 9 March 2023 and are subject to approval by the Annual General meeting on 12 April 2023.